{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/diagnosis/assessment-diagnosis/","result":{"pageContext":{"chapter":{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis","depth":2,"htmlHeader":"<!-- begin field b0ff1f7d-f8a5-4ab4-a113-e1a2f425c2d4 --><h2>How should I assess a person with possible familial hypercholesterolaemia?</h2><!-- end field b0ff1f7d-f8a5-4ab4-a113-e1a2f425c2d4 -->","summary":"","htmlStringContent":"<!-- begin item 8b59440f-eee1-44ec-b51a-1a0f8dd189c3 --><!-- begin field 3f7159cd-3df4-4aa0-8b07-951af9d88f11 --><ul><li><strong>If familial hypercholesterolaemia (FH) is suspected, assess the person. </strong>(Consider referring children and young people [up to 15 years of age] to a specialist for the assessment to be carried out.)<ul><li>Take two measurements of low-density lipoprotein (LDL) cholesterol concentration.<ul><li><strong>Consider a clinical diagnosis of homozygous FH </strong>in adults with LDL cholesterol concentration greater than 13 mmol/L.</li><li><strong>Consider a clinical diagnosis of homozygous FH</strong> in a child or young person (up to 15 years of age) with an LDL cholesterol concentration greater than 11 mmol/L.</li></ul></li><li>Look for clinical signs of FH, such as<em> </em><a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/diagnosis/assessment-diagnosis/#tendon-xanthomata\">tendon xanthomata</a>, but be aware that the absence of clinical signs does not exclude a diagnosis of FH.</li><li>Exclude <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/diagnosis/assessment-diagnosis/#secondary-hypercholesterolaemia\">secondary hypercholesterolaemia</a>.<ul><li>An underlying cause can usually be detected from the history and examination and by checking thyroid stimulating hormone, HbA1c, renal function, electrolytes, and liver function.</li><li>An underlying condition or drug may be exacerbating primary FH, and serum lipids should be rechecked (if possible) after the condition has resolved or the drug has been stopped.</li></ul></li></ul></li><li><strong>Use the <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/diagnosis/assessment-diagnosis/#the-simon-broome-the-dutch-lipid-clinic-network-criteria\">Simon Broome</a> criteria or the <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/diagnosis/assessment-diagnosis/#the-simon-broome-the-dutch-lipid-clinic-network-criteria\">Dutch Lipid Clinic Network</a> (DLCN) criteria to aid clinical diagnosis of FH in primary care. </strong>This should be done by a healthcare professional competent in using the criteria. <ul><li>Make a clinical diagnosis of FH in people who meet the Simon Broome criteria for 'possible' or 'definite' FH, or have a DLCN score greater than 5. </li><li>Be aware that the Simon Broome criteria has different lipid concentration levels for adults and children.</li></ul></li><li><strong>Refer all people with a clinical diagnosis of FH (heterozygous or homozygous) to a specialist for confirmation of the diagnosis and initiation of cascade testing</strong> (which involves identification of affected relatives by DNA testing).<ul><li>Ideally, children and young people should be referred to a specialist with particular expertise in FH in children and young people. If unavailable locally, refer to a specialist with expertise in FH (usually at a lipid or metabolic clinic). Diagnosis should be made by 10 years of age or at the earliest opportunity thereafter.</li></ul></li></ul><!-- end field 3f7159cd-3df4-4aa0-8b07-951af9d88f11 --><!-- end item 8b59440f-eee1-44ec-b51a-1a0f8dd189c3 -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"13588941-b46f-5306-a752-0527c4458410","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"02dc97e2-72ab-5c6c-9ded-24c0864655ce","slug":"tendon-xanthomata","fullItemName":"Tendon xanthomata","depth":3,"htmlHeader":"<!-- begin field 0433425e-6521-49e8-9b8f-aa02000e60c2 --><h3>Tendon xanthomata</h3><!-- end field 0433425e-6521-49e8-9b8f-aa02000e60c2 -->","summary":null,"htmlStringContent":"<!-- begin item 2e5a4daf-f534-4438-aa8a-aa02000e60ad --><!-- begin field 2d6a1848-5fdb-43af-aae9-aa02000e60c2 --><ul><li>Tendon xanthomata are hard, non-tender, nodular enlargements of tendons most commonly found on the dorsum (knuckles) of the hands and in the Achilles tendons, but may rarely be present on the extensor hallucis longus and triceps tendons. <ul><li>They feel hard because they are fibrotic, and may become inflamed in the Achilles tendons (sometimes presenting as chronic Achilles tenosynovitis, which may be exacerbated by a statin).</li><li>Because the overlying skin is of normal colour, they may be difficult to detect.</li></ul></li><li>Tendon xanthomata appear in people with heterozygous familial hypercholesterolaemia (FH) from 20 years of age onwards (unless the person was started on a statin early in life), but are often evident in homozygous FH from childhood.<ul><li>They are highly suggestive of FH, but their absence does not exclude FH.</li><li>Other types of xanthomata (such as xanthelasmata on the eyelids) and premature corneal arcus may occur in people with FH, but they are less specific.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">WHO, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Winder et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Warrell et al, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Moruisi et al, 2006</a>]</p><!-- end field 2d6a1848-5fdb-43af-aae9-aa02000e60c2 --><!-- end item 2e5a4daf-f534-4438-aa8a-aa02000e60ad -->","subChapters":[]},{"id":"f9c81187-d185-5610-b33e-3eb55e501515","slug":"secondary-hypercholesterolaemia","fullItemName":"Secondary hypercholesterolaemia","depth":3,"htmlHeader":"<!-- begin field f2f159d9-da7c-485e-8c2d-aa02000dfcce --><h3>Causes of secondary hypercholesterolaemia</h3><!-- end field f2f159d9-da7c-485e-8c2d-aa02000dfcce -->","summary":null,"htmlStringContent":"<!-- begin item 7f2bedc9-dae0-4aa0-9f5b-aa02000dfcb9 --><!-- begin field 06199bd3-6fb1-4229-b8b7-aa02000dfcce --><ul><li><strong>The following conditions may cause hypercholesterolaemia (without hypertriglyceridaemia):</strong><ul><li>Hypothyroidism. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li>Cholestatic liver disease (such as primary biliary cirrhosis).</li><li>Nephrotic syndrome.</li><li>Cushing's syndrome.</li><li>Anorexia nervosa. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eating-disorders/\">Eating disorders</a> for more information.</li><li>The use of certain drugs, including androgens and ciclosporin.</li></ul></li><li><strong>The following conditions may also cause hypercholesterolaemia, but, usually, hypertriglyceridaemia would also be present:</strong><ul><li>Diabetes mellitus or obesity (although hypertriglyceridaemia alone is the more common presentation). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li>Pregnancy.</li><li>Renal replacement therapy or end-stage chronic kidney disease. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>Monoclonal gammopathy.</li><li>Excess alcohol consumption. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information.</li><li>HIV infection. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a> for more information.</li><li>The use of certain drugs, including thiazide diuretics, corticosteroids, retinoic acid derivatives, beta-blockers, and anti-retrovirals (protease inhibitors and nucleoside analogue reverse transcriptase inhibitors, such as stavudine).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Aronson, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Bhatnagar et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Durrington, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">ABPI, 2018a</a>]</p><!-- end field 06199bd3-6fb1-4229-b8b7-aa02000dfcce --><!-- end item 7f2bedc9-dae0-4aa0-9f5b-aa02000dfcb9 -->","subChapters":[]},{"id":"269e78da-f84e-5a92-9403-2bd6e3d855da","slug":"the-simon-broome-the-dutch-lipid-clinic-network-criteria","fullItemName":"The Simon Broome and the Dutch Lipid Clinic Network criteria","depth":3,"htmlHeader":"<!-- begin field 50487779-5ed4-476d-926c-a9fa00d2ddc5 --><h3>The Simon Broome and the Dutch Lipid Clinic Network criteria</h3><!-- end field 50487779-5ed4-476d-926c-a9fa00d2ddc5 -->","summary":null,"htmlStringContent":"<!-- begin item 8b7b950d-1868-477a-93c8-a9fa00d2dd47 --><!-- begin field 216f442c-377f-46a1-9621-a9fa00d2ddc5 --><ul><li><strong>The Simon Broome criteria include cholesterol concentrations, clinical characteristics, molecular diagnosis, and family history. Using this criteria:</strong><ul><li>'Definite'<em> </em>familial hypercholesterolaemia (FH) is defined as total cholesterol greater than 6.7 mmol/L or low-density lipoprotein (LDL) cholesterol concentration greater than 4.0 mmol/L in a child aged younger than 16 years or total cholesterol greater than 7.5 mmol/L or LDL cholesterol concentration greater than 4.9 mmol/L in an adult (levels either pre-treatment or highest on treatment), <em>plus</em><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/diagnosis/assessment-diagnosis/#tendon-xanthomata\">Tendon xanthomata</a> (or evidence of tendon xanthomata) in  the person, a first-degree relative (parent, sibling, or child) or a second-degree relative (grandparent, uncle, or aunt), <em>or</em></li><li>DNA-based evidence of an LDL receptor mutation, familial defective apo B-100, or a PCSK9 mutation.</li></ul></li><li>'Possible' FH is defined as total cholesterol greater than 6.7 mmol/L or LDL cholesterol greater than 4.0 mmol/L in a child aged younger than 16 years or total cholesterol greater than 7.5 mmol/L or LDL cholesterol greater than 4.9 mmol/L in an adult (levels either pre-treatment or highest on treatment), <em>and </em>at least one of the following:<ul><li>Family history of myocardial infarction — before 60 years of age in a first-degree relative or before 50 years of age in a second-degree relative.</li><li>Family history of raised total cholesterol — greater than 7.5 mmol/L in an adult first- or second-degree relative, or greater than 6.7 mmol/L in a child or sibling (of the person with suspected FH) aged younger than 16 years.</li></ul></li></ul></li><li><strong>Using the Dutch Lipid Clinic Network criteria, points are assigned for family history of hyperlipidaemia or heart disease, clinical characteristics (such as tendon xanthomata), elevated LDL cholesterol, and/or an identified mutation. </strong>The higher the score, the higher the likelihood of the person having FH. See Table 1 for more information.</li></ul><p><strong>Table 1.</strong> Dutch Lipid Clinic Network Criteria for making a diagnosis of familial hypercholestrolaemia.</p><table data-table-id=\"4c332f79-324c-4af9-bacc-acce014f877e\"><thead><tr><th scope=\"col\"> </th><th scope=\"col\">Score</th></tr></thead><tbody><tr><td><strong>Family history</strong></td><td> </td></tr><tr><td><p>First-degree relative (parent, sibling, or child) with known premature coronary and/or vascular disease (men aged younger than 55 years and women aged younger than 60 years), <em>or</em></p><p>First-degree relative with known low-density lipoprotein (LDL) cholesterol above the 95th percentile for age and sex</p></td><td>1</td></tr><tr><td><p>First-degree relative with tendon xanthomata and/or arcus cornealis, <em>or</em></p><p>Children aged younger than 18 years with LDL cholesterol above the 95th percentile for age and sex </p></td><td>2</td></tr><tr><td><strong>Clinical history</strong></td><td> </td></tr><tr><td>People with premature coronary artery disease (men aged younger than 55 years and women aged younger than 60 years)</td><td>2</td></tr><tr><td>People with premature cerebral or peripheral vascular disease (men aged younger than 55 years and women aged younger than 60 years)</td><td>1</td></tr><tr><td><strong>Physical examination</strong></td><td> </td></tr><tr><td>Tendon xanthomata</td><td>6</td></tr><tr><td>Arcus cornealis prior to 45 years of age</td><td>4</td></tr><tr><td><strong>Investigations</strong></td><td> </td></tr><tr><td>LDL cholesterol<strong> </strong>of 8.5 mmol/L or more</td><td>8</td></tr><tr><td>LDL cholesterol 6.5–8.4 mmol/L</td><td>5</td></tr><tr><td>LDL cholesterol 5.0–6.4 mmol/L</td><td>3</td></tr><tr><td>LDL cholesterol 4.0–4.9 mmol/L</td><td>1</td></tr><tr><td><strong>DNA analysis</strong></td><td> </td></tr><tr><td>Functional mutation in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB) or proprotein convertase subtilisin/kexin type 9 (PCSK9) gene</td><td>8</td></tr><tr><td colspan=\"2\"><strong>Stratification based on total score</strong></td></tr><tr><td>'Definite' FH</td><td>> 8 </td></tr><tr><td>'Probable' FH</td><td>6–8</td></tr><tr><td>'Possible' FH</td><td>3–5</td></tr><tr><td>'Unlikely' FH</td><td>< 3</td></tr><tr><td colspan=\"2\"><strong>Data adapted from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">WHO, 1998</a>]</td></tr></tbody></table><!-- end field 216f442c-377f-46a1-9621-a9fa00d2ddc5 --><!-- end item 8b7b950d-1868-477a-93c8-a9fa00d2dd47 -->","subChapters":[]},{"id":"022a783c-e103-5dc5-bc14-9a3a20be273a","slug":"basis-for-recommendation-bbc","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field d4293317-d277-414f-b7f3-57e9777bdbdb --><h3>Basis for recommendation</h3><!-- end field d4293317-d277-414f-b7f3-57e9777bdbdb -->","summary":null,"htmlStringContent":"<!-- begin item bbc94e66-9e6c-4b46-a922-fc9a0145f963 --><!-- begin field cd08b73e-81b1-4195-8012-2f5a2cc9c1c4 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Identification and management of familial hypercholesterolaemia (Full guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>] and <em>Familial hypercholesterolaemia: identification and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>]<em>. </em></p><h4>Measuring low-density lipoprotein (LDL) cholesterol</h4><ul><li>NICE recommends two measurements of LDL cholesterol because biological and analytical variability occurs between samples. The NICE guideline development group agreed that confirmation of the cholesterol concentration at diagnosis should be undertaken before considering people for further investigation and lifelong management for familial hypercholesterolaemia (FH).</li></ul><h4>Excluding secondary causes of hypercholesterolaemia</h4><ul><li>NICE recommends that secondary causes of hypercholesterolaemia should be excluded before a diagnosis of FH is considered.</li><li>The methods suggested for excluding secondary hypercholesterolaemia are based on expert opinion in a textbook on clinical medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Kumar and Clark, 2012</a>].</li></ul><h4>Using the Simon Broome or the Dutch Lipid Clinic Network (DLCN) criteria to make a clinical diagnosis of FH in primary care</h4><ul><li>NICE recommends the Simon Broome diagnostic criteria because they are validated, their development was based on a UK population, and they are simpler to use than other criteria, with a comparable or better positive likelihood ratio. </li><li>The Dutch Lipid Clinic Network criteria is also recommended because they are similar to the Simon Broome Register criteria. </li></ul><!-- end field cd08b73e-81b1-4195-8012-2f5a2cc9c1c4 --><!-- end item bbc94e66-9e6c-4b46-a922-fc9a0145f963 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}